title: Intravenous immunoglobulin treatment on anti-GM1 antibodies associated neuropathies inhibits cholera toxin and galectin-1 binding to ganglioside GM1.
abstract: Intravenous immunoglobulin (IVIg) therapy is efficacious in some peripheral nervous autoimmune diseases associated with anti-GM1 antibodies. Numerous mechanisms of action have been proposed to account for the immunomodulatory effects of IVIg in immune-mediated diseases. Up to now, the mechanisms of action of IVIg in pathology associated with anti-GM1 antibodies have not been well documented. In the present study, we discovered that IVIg did not inhibit the binding of anti-GM1 antibodies to its antigen and IVIg perfusions did not reduce anti-GM1 antibodies titers. In this observation, we have the result different from the hypothesis of presence of anti-idiotypic antibodies in different IVIg preparations, and show that IVIg inhibits the binding of cholera toxin and galectin-1 to GM1-expressing cells using flow cytometry. Our results suggest that the correct ratio galactosyl/agalactosyl IgG in IVIg interact with macrophages receptors to down-regulate inflammatory function of macrophages and autoimmune diseases in peripheral nerve system.
authors.affiliation: Shanghai XuHui Centre Hospital, 966 HuaiHai Zhong Road, Shanghai 200031, PR China; Laboratoire d'Immunologie, Faculté de Médecine de Marseille, Université de la Méditerannée, 27 Boulevard Jean Moulin 13385 Marseille Cedex 5, France. pengwei39@hotmail.com
authors.forename: Wei
authors.initials: W
authors.lastname: Peng
mesh_terms: D001323:Autoantibodies / Q000097:blood / Q000276:immunology*; D001324:Autoantigens; D020274:Autoimmune Diseases of the Nervous System / Q000188:drug therapy* / Q000276:immunology; D002460:Cell Line; D002462:Cell Membrane / Q000378:metabolism; D002772:Cholera Toxin / Q000378:metabolism*; D005677:G(M1) Ganglioside / Q000276:immunology* / Q000378:metabolism*; D037483:Galectin 1 / Q000378:metabolism*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000494:pharmacology / Q000627:therapeutic use*; D011485:Protein Binding / Q000187:drug effects / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D001323:Autoantibodies; D001324:Autoantigens; D037483:Galectin 1; D016756:Immunoglobulins, Intravenous; D005677:G(M1) Ganglioside; D002772:Cholera Toxin